# Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers

> **NCT02252211** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 9 (actual)

## Conditions studied

- Malignant Solid Tumor
- Metastatic EphA2 Positive Cancer

## Interventions

- **DRUG:** DS-8895a 1 mg/kg
- **DRUG:** DS-8895a 3 mg/kg
- **DRUG:** DS-8895a 10 mg/kg

## Key facts

- **NCT ID:** NCT02252211
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2016-09-08
- **Final completion:** 2016-09-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252211, "Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02252211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*